Let's look at the challenges and opportunities facing these Big Pharma stocks to see which is most attractive now.
Inherent advantages in the healthcare system for drugmakers are fueling soaring drug prices.
A high-profile failure in lung cancer patients punished Bristol-Myers Squibb's invetors and rewarded Merck & Co.'s investors.
If you buy and hold stocks with these three traits, you can catch these fat yields, too!
Looking for inexpensive stocks to ride an aging demographic trend? These five Big Pharma stocks are trading at steep discounts.
Don't blink, otherwise you could miss another innovative cancer drug hitting pharmacy shelves.
This experimental anti-cancer drug has jaw-dropping commercial potential.
Investment decisiones should be based on future potential, not past dividend growth.
Gilead's pan-genotypic hepatitis C virus combo, Epclusa, could significantly boost the company's sales by filling some important niches.
The approval of Epclusa could shake up how doctors treat hepatitis C patients with tough-to-treat genotypes of the disease.